Glenmark Pharmaceuticals shines after ANDA approval
DSIJ Intelligence / 10 Apr 2017
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Fenofibrate Capsules.
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Fenofibrate Capsules. The capsules USP, 67 mg, 134 mg and 200 mg are the generic version of Tricor Micronized Capsules, 67 mg, 134 mg and 200 mg of AbbVie Inc.
According to IMS Health's sales data for the 12-month period ending February 2017, the Tricor Micronized Capsules, 67 mg, 134 mg and 200 mg have achieved annual sales of approximately USD 97.5 million (Rs 628 crore).
Glenmark Pharmaceuticals’ current portfolio consists of 114 products authorised for distribution in the US marketplace. Approximately 64 ANDAs of the company are pending for approval with the USFDA. At the same time, it continues to identify and explore external development partnerships for supplementing and accelerating the growth of its existing pipeline and portfolio.
The stock price of Glenmark Pharmaceuticals increased 1.19 per cent in early trade, and is trading at Rs 867.4 on an intraday basis.